Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BACTS2
MCID: BCT020
MIFTS: 48

Bacteremia 2 (BACTS2)

Categories: Genetic diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Bacteremia 2

About this section

MalaCards integrated aliases for Bacteremia 2:

Name: Bacteremia 2 57
Bacteremia 57 53 71 75
Bacteremia, Susceptibility to, 2 57 28 5
Bacteremia, Susceptibility to, Type 2 38
Bacteremia, Susceptibility to 57
Bacts2 57

Classifications:

MalaCards categories:
Global: Genetic diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 614383
UMLS 71 C0004610
Sources

Summaries for Bacteremia 2

About this section

MalaCards based summary: Bacteremia 2, also known as bacteremia, is related to meningococcal infection and toxic shock syndrome. An important gene associated with Bacteremia 2 is CISH (Cytokine Inducible SH2 Containing Protein), and among its related pathways/superpathways are Innate Immune System and Interleukin-7 signaling. The drugs Ampicillin and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include skin, bone marrow and whole blood, and related phenotype is homeostasis/metabolism.

More information from OMIM: 614383
Sources

Related Diseases for Bacteremia 2

About this section

Diseases in the Bacteremia 2 family:

Bacteremia 1

Diseases related to Bacteremia 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1106)
# Related Disease Score Top Affiliating Genes
1 meningococcal infection 31.8 MBL2 LACTB
2 toxic shock syndrome 31.4 LBP CRP BPI
3 pneumonia 31.1 SLPI MBL2 LBP LACTB CRP
4 cellulitis 31.0 LACTB CRP
5 meningitis 30.9 MBL2 LBP LACTB CRP
6 bacteriuria 30.6 CRP CAT
7 otitis media 30.6 MBL2 LACTB CRP
8 gastroenteritis 30.6 LACTB GUSB CRP
9 epiglottitis 30.6 LACTB CRP
10 klebsiella pneumonia 30.5 LACTB CRP
11 lung abscess 30.5 LACTB CRP
12 adult respiratory distress syndrome 30.5 SLPI LBP CRP
13 aspiration pneumonia 30.4 LACTB CRP
14 mediastinitis 30.3 LACTB CRP
15 bacterial meningitis 30.2 LACTB GUSB CRP
16 vasculitis 30.2 MBL2 CRP BPI
17 intracranial abscess 30.2 LACTB CRP
18 reactive arthritis 30.2 LBP CRP BPI
19 gas gangrene 30.1 HMGCR CRP
20 erysipelas 30.1 CRP CAT
21 bronchopneumonia 30.0 GUSB CRP
22 bronchitis 29.9 SLPI LACTB CRP
23 mycobacterium tuberculosis 1 29.9 MBL2 MAPKAPK3 CRP CISH
24 diabetes mellitus, ketosis-prone 29.8 GCG CRP
25 choledocholithiasis 29.7 GUSB CRP
26 syphilis 29.7 LACTB CRP CAT
27 endocarditis 29.7 LBP LACTB CRP
28 vaginal discharge 29.7 SLPI CRP
29 aphthous stomatitis 29.7 MBL2 CRP
30 mastitis 29.7 SLPI LBP LACTB BPI
31 cholelithiasis 29.7 HMGCR GUSB CRP
32 volvulus of midgut 29.6 GCG CRP
33 pelvic inflammatory disease 29.6 LACTB GUSB CRP
34 bacterial infectious disease 29.5 MBL2 LBP CRP BPI
35 bronchiectasis 29.4 SLPI MBL2 CRP BPI
36 cerebral palsy 29.4 SMARCA4 MBL2 CRP CAT
37 nasopharyngitis 29.4 GCG CRP
38 haverhill fever 29.3 GUSB CRP
39 cystic fibrosis 28.5 SMARCA4 SLPI MBL2 LBP LACTB GUSB
40 type 2 diabetes mellitus 28.1 HMGCR GUSB GCG CRP CISH CAT
41 bacteremia 1 11.5
42 flavimonas oryzihabitans infection 11.0
43 erysipeloid 11.0
44 trench fever 11.0
45 bartonellosis 11.0
46 actinobacillosis 10.9
47 immunodeficiency 72 with autoinflammation 10.9
48 typhoidal tularemia 10.9
49 klebsiella infection 10.9
50 neutropenia 10.8

Comorbidity relations with Bacteremia 2 via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bacteremia 2:



Diseases related to Bacteremia 2
Sources

Symptoms & Phenotypes for Bacteremia 2

About this section

Clinical features from OMIM®:

614383 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Bacteremia 2:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.36 CAT CISH CRP GCG GUSB HMGCR
Sources

Drugs & Therapeutics for Bacteremia 2

About this section

Drugs for Bacteremia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
2
Cefuroxime Approved Phase 4 55268-75-2 5479529
3
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
4
Carbamide peroxide Approved Phase 4 124-43-6
5
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
9
Hexetidine Approved, Investigational Phase 4 141-94-6 3607
10
Ethambutol Approved Phase 4 74-55-5, 1070-11-7 3279 14052
11
Rifabutin Approved, Investigational Phase 4 72559-06-9 46783538 6323490
12
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
13
Taurolidine Approved, Investigational Phase 4 19388-87-5
14
Cefazolin Approved Phase 4 25953-19-9 33255
15
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
16
Tazobactam Approved Phase 4 89786-04-9 123630
17
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
18
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Tigecycline Approved Phase 4 220620-09-7 5282044
21
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
22
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
23
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
24
Benzylpenicillin Approved, Vet_approved Phase 4 61-33-6 5904
25
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5, 39831-55-5 37768
26
Avibactam Approved Phase 4 1192500-31-4
27
Flucloxacillin Approved, Investigational Phase 4 5250-39-5, 34214-51-2 21319
28
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509 3000540
29
Vancomycin Approved Phase 4 1404-90-6 14969
30
Meticillin Approved, Investigational Phase 4 61-32-5 6087
31
Nafcillin Approved, Investigational Phase 4 985-16-0, 147-52-4 8982
32
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
33
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3 72562361
34
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
35
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
36
Cloxacillin Approved, Investigational, Vet_approved Phase 4 61-72-3 6098
37
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
38
Fosfomycin Approved Phase 4 23155-02-4 446987
39
Povidone-iodine Approved Phase 4 25655-41-8
40
Iodine Approved, Investigational Phase 4 7553-56-2 807
41
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
43
Octenidine Investigational Phase 4 71251-02-0
44
Cadexomer iodine Experimental Phase 4 94820-09-4
45
Cefuroxime axetil Phase 4 3379942
46 Pharmaceutical Solutions Phase 4
47 Fibrinolytic Agents Phase 4
48 Calcium heparin Phase 4
49 Anticoagulants Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 283)
# Name Status NCT ID Phase Drugs
1 Efficacy of Seven and Fourteen Days of Antibiotic Treatment in Uncomplicated Staphylococcus Aureus Bacteremia: A Randomized, Non-blinded, Non-inferiority Interventional Study Unknown status NCT03514446 Phase 4 Antibiotic therapy duration for 7 days
2 Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia Unknown status NCT03108690 Phase 4 Continuous infusion of beta-lactam antibiotics .
3 Concentration and Antibiotic Activity in Antibiotic Lock Solutions Unknown status NCT01592032 Phase 4 Vancomycin antimicrobial-lock solution;Teicoplanin antimicrobial-lock solution;Linezolid antimicrobial-lock solution;Daptomycin antimicrobial-lock solution;Tigecycline antimicrobial-lock solution
4 A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Completed NCT01701219 Phase 4 Ceftaroline fosamil
5 Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia Completed NCT02972983 Phase 4 Daptomycin
6 A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia Completed NCT02660346 Phase 4 Daptomycin;Vancomycin;Ceftaroline
7 Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Completed NCT00294502 Phase 4 Gentamycin/citrate, Minocycline/EDTA
8 An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3 Completed NCT00002343 Phase 4 Ethambutol hydrochloride;Rifabutin
9 Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia Completed NCT00609375 Phase 4 cefepime
10 Influence of Pre-procedural Oral Rinse in the Induced Bacteremia by Periodontal Instrumentation: a Randomized Clinical Trial Completed NCT02215473 Phase 4 Chlorhexidine gluconate mouth rinse
11 A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus. Completed NCT01728376 Phase 4 Daptomycin;Comparator
12 The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients Completed NCT01919593 Phase 4 2% chlorhexidine gluconate in 70% alcohol;10%povidone iodine
13 Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial Completed NCT00515151 Phase 4 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol;74% Ethanol with 10% 2-propanol
14 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
15 Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU Completed NCT00417235 Phase 4
16 Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Completed NCT03627884 Phase 4 Sodium Bicarbonate Catheter Lock Solution;Normal Saline Catheter Lock Solution
17 Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial Completed NCT00571259 Phase 4 Heparin 1000U/mL;4% Sodium Citrate with Gentamicin 320 mcg/mL
18 The VANcomycin Cohort Study - Assessing Precise Dosing and Prompt Drug Monitoring to Improve Attainment of Target Concentrations (Part 1) Completed NCT04044703 Phase 4 Vancomycin - model-based dosing regimen
19 Evaluation of Antimicrobial Use and Time of Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction (PCR) in Real Time Multiplex to the Conventional Blood Culture for Etiologic Agents Identification. Randomized Clinical Trial. Completed NCT01450358 Phase 4
20 Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols Completed NCT02150031 Phase 4 0.2% Chlorhexidine;1% Chlorhexidine;Lidocaine plus adrenaline
21 Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of a Standard Central Venous Catheter (CVC) in Comparison to a Coated CVC Completed NCT00555282 Phase 4
22 Prospective Trial for Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction Completed NCT02789501 Phase 4
23 Effects of Ultrasonic Debridement With PVP-iodine Irrigation on Post-treatment Bacteraemia Compared to Ultrasonic Debridement With Water Completed NCT01647347 Phase 4 Supra- and subgingival rinsing with 10% PVP-iodine
24 A Randomised Controlled Trial of Taurolidine With Heparin for Prevention of Recurrence of Catheter Related Bacteraemia in Haemodialysis Patients. Completed NCT01243710 Phase 4
25 Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study Recruiting NCT04291768 Phase 4
26 Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteremia: a Multicenter, Randomized Clinical Trial (SHORTEN-2) With a DOOR / RADAR Analysis Recruiting NCT05210439 Phase 4 Short-treatment of any active antibiotic regimen;Long-treatment of any active antibiotic regimen
27 Randomized Non-inferiority Clinical Trial to Evaluate the Effectiveness and Security of Therapy for Non Complicated Enterococcal Bacteremia. Recruiting NCT05394298 Phase 4 Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.;Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
28 Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial Recruiting NCT03671967 Phase 4 Piperacillin/tazobactam;Meropenem
29 AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTS Recruiting NCT04882085 Phase 4 Zavicefta, Ceftazidime-Avibactam;Best Available Treatment
30 Staphylococcus Aureus Network Adaptive Platform Trial Recruiting NCT05137119 Phase 4 Cefazolin;Penicillin;Clindamycin;Vancomycin
31 PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN Trial Recruiting NCT05355350 Phase 4 Piperacillin / Tazobactam Injection;Meropenem
32 Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections Not yet recruiting NCT05521880 Phase 4 Oritavancin
33 An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Terminated NCT02783404 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate
34 A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment Terminated NCT01104662 Phase 4 Vancomycin;Daptomycin;Semi-Synthetic Penicillin
35 Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) Terminated NCT01287832 Phase 4 Vancomycin;Daptomycin
36 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
37 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
38 Multicenter, Randomised, Open-label Phase III-IV Study to Evaluate the Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: SAFO Trial Terminated NCT03959345 Phase 4 Combination therapy group;Standard therapy group
39 A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections Terminated NCT03447639 Phase 4 Povidone-iodine irrigation
40 Clinical Phase IV Comparison Trial for 2% Chlorhexidine Skin Asepsis +70% Alcohol Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia in Critical Patients: Preliminary Study Withdrawn NCT03489512 Phase 4 A (Chloraprep);B (Clorhexidine 2%)
41 A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder Withdrawn NCT03761953 Phase 4 Oritavancin Injection
42 Simplified Selective Digestive Tract Decontamination for the Prevention of ICU Infections in the Setting of High-level Antibiotic Resistance Unknown status NCT01798537 Phase 2, Phase 3 Neomycin Colistin Nystatin Vancomycin
43 Lock Con Etanolo Per il Salvataggio di Dispositivi Vascolari a Lungo Termine. Un Trial Clinico Multicentrico Controllato Randomizzato Unknown status NCT01186172 Phase 3 Ethanol-lock therapy;Antibiotic-lock
44 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
45 Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae Completed NCT02795949 Phase 3 Antipseudomonal beta-lactam antibiotic;De-escalation(short-spectrum antibiotic)
46 A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia) Completed NCT01967225 Phase 3 Tedizolid Phosphate (Sivextro, BAY1192631);Linezolid
47 Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure Completed NCT02142075 Phase 3 Daptomycin
48 Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients Completed NCT01898338 Phase 3 Fosfomycin 2gr/6h iv;Daptomycin 10mg/kg/24h iv
49 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
50 A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo Completed NCT00002101 Phase 3 Ethambutol hydrochloride;Clarithromycin;Rifabutin

Search NIH Clinical Center for Bacteremia 2

Sources

Genetic Tests for Bacteremia 2

About this section

Genetic tests related to Bacteremia 2:

# Genetic test Affiliating Genes
1 Bacteremia, Susceptibility to, 2 28 CISH
Sources

Anatomical Context for Bacteremia 2

About this section

Organs/tissues related to Bacteremia 2:

MalaCards : Skin, Bone Marrow, Whole Blood, Myeloid, Liver, Lung, Neutrophil
Sources

Publications for Bacteremia 2

About this section

Articles related to Bacteremia 2:

(show top 50) (show all 26053)
# Title Authors PMID Year
1
CISH and susceptibility to infectious diseases. 62 57 5
20484391 2010
2
Bacteremia among children admitted to a rural hospital in Kenya. 62 57
15635111 2005
3
Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. 57
9465889 1997
4
[Diagnostic value of procalcitonin, interleukin 8, interleukin 6, and C-reactive protein for detecting bacteremia and fungemia in cancer patients]. 53 62
20097454 2010
5
Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. 53 62
20423493 2010
6
[Risk factors for extended espectrum beta-lactamase producer E.coli bacteremia from urinary origin]. 53 62
20044105 2010
7
Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. 53 62
20146986 2010
8
[Post-operative bacteremia caused by multidrug-resistant Aerococcus viridans in a patient with gall bladder cancer]. 53 62
20455408 2010
9
USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. 53 62
19820424 2009
10
C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. 53 62
19664100 2009
11
Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. 53 62
19675218 2009
12
Predictors of mortality in patients with bacteremia of unknown source due to extended spectrum beta-lactamase producing Escherichia coli. 53 62
19622466 2009
13
Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. 53 62
19949753 2009
14
Risk index score for bacteremia in febrile neutropenic episodes in children with malignancies. 53 62
19810131 2009
15
Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. 53 62
19526164 2009
16
Polymorphic receptors of the innate immune system (MBL/MASP-2 and TLR2/4) and susceptibility to pneumococcal bacteremia in HIV-infected patients: a case-control study. 53 62
19275590 2009
17
Risk factors for negative blood cultures in adult medical inpatients--a retrospective analysis. 53 62
18957115 2008
18
Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. 53 62
18661397 2008
19
C reactive protein (CRP) as a predictor for true bacteremia in children. 53 62
18443549 2008
20
Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone. 53 62
17996417 2008
21
Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. 53 62
18056482 2008
22
[Total white blood cell count, erythrosedimentation rate and C-reactive protein for the detection of serious bacterial infections in 0- to 90-day-old infants with fever without a source]. 53 62
18341874 2008
23
New-onset atrial fibrillation in bacteremia is not associated with C-reactive protein, but is an indicator of increased mortality during hospitalization. 53 62
18434721 2008
24
Community-acquired thoracic empyema in young adults. 53 62
17984736 2007
25
[Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures]. 53 62
18173077 2007
26
Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study. 53 62
17868441 2007
27
Gallstones containing bacteria are biofilms: bacterial slime production and ability to form pigment solids determines infection severity and bacteremia. 53 62
17546479 2007
28
Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. 53 62
17640342 2007
29
Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. 53 62
17143875 2007
30
The role of statin therapy in sepsis. 53 62
17389664 2007
31
The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. 53 62
17356388 2007
32
Association between mannose-binding lectin deficiency and septic shock following acute pyelonephritis due to Escherichia coli. 53 62
17202308 2007
33
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. 53 62
17202380 2007
34
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. 53 62
16547275 2006
35
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. 53 62
16569837 2006
36
[Fever in patients of a Service of Internal Medicine: prospective study in 204 cases]. 53 62
16566652 2006
37
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. 53 62
16323119 2006
38
Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. 53 62
15808312 2005
39
Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. 53 62
16761394 2005
40
Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. 53 62
15711657 2004
41
Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients. 53 62
15480883 2004
42
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. 53 62
15319865 2004
43
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. 53 62
15206050 2004
44
Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. 53 62
15221617 2004
45
C-reactive protein in the diagnosis of melioidosis. 53 62
15155996 2004
46
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. 53 62
14706969 2004
47
Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. 53 62
14699457 2004
48
Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. 53 62
14569424 2003
49
Plasma secretory leukocyte protease inhibitor in febrile patients. 53 62
12925099 2003
50
Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. 53 62
12499183 2003
Sources

Variations for Bacteremia 2

About this section

ClinVar genetic disease variations for Bacteremia 2:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CISH, MAPKAPK3 NM_001243926.2(MAPKAPK3):c.-436A>T SNV Risk Factor
 7091 rs414171 GRCh37: 3:50649499-50649499
GRCh38: 3:50612068-50612068
Sources

Expression for Bacteremia 2

About this section
Search GEO for disease gene expression data for Bacteremia 2.
Sources

Pathways for Bacteremia 2

About this section

Pathways related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 12.88 SMARCA4 SLPI MBL2 MAPKAPK3 LBP GUSB
2
Interleukin-7 signaling 66
10.71 SMARCA4 CISH
3
EGR2 and SOX10-mediated initiation of Schwann cell myelination 66
10.4 SMARCA4 HMGCR
Sources

GO Terms for Bacteremia 2

About this section

Cellular components related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SLPI MBL2 LBP GUSB GCG CRP
2 extracellular space GO:0005615 9.55 SMARCA4 SLPI MBL2 LBP GUSB GCG

Biological processes related to Bacteremia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.96 SLPI MBL2 LBP CRP BPI
2 defense response to Gram-positive bacterium GO:0050830 9.8 MBL2 LBP CRP
3 defense response to bacterium GO:0042742 9.55 SLPI MBL2 LBP BPI
4 acute-phase response GO:0006953 9.43 MBL2 LBP CRP
5 opsonization GO:0008228 9.1 MBL2 LBP CRP
Sources

Sources for Bacteremia 2

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....